Showing 1771-1780 of 2192 results for "".
- Opioid Use for Migraine Treatment Remains High, Especially in Emergency Departmenthttps://practicalneurology.com/news/opioid-use-for-migraine-treatment-remains-high-especially-when-treatment-occurs-in-the-emergency-department/2468955/A retrospective analysis of electronic health records from 2010 through 2016 evaluated 14,494 emergency department visits for migraine. In 23%, opioids were given within 12 hours of presentation. When opioids were given, they were the first therapy given more than half the time (58%). Likelihood
- Last Patient Fully Assessed in Trial of Accordion Formulation of Levodopa/Carbidopa for Parkinson's Diseasehttps://practicalneurology.com/news/last-patient-fully-assessed-in-trial-of-accordion-formulation-of-levodopacarbidopa-for-parkinsons-disease/2468878/The final patient completed their last physician visit in a pivotal phase 3 clinical trial for the accordion pill formulation of carbidopa/levodopa (AP-CD/LD) (Intec Pharma, Jerusalem, Israel) for treating advanced Parkinson’s disease (PD). A gastric-retentive drug delivery sy
- FDA Expands Selumetinib Approval to Younger Pediatric Patients with NF1https://practicalneurology.com/news/fda-expands-selumetinib-approval-to-younger-pediatric-patients-with-nf1/2483375/The Food and Drug Administration (FDA) announced the expanded approval of Koselugo (selumetinib; AstraZeneca, Wilmington, DE) to include pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The ther
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- 6-Year Data Reported for Kesimpta Treatment of Individuals with Early, Non-Highly Active MShttps://practicalneurology.com/news/6-year-data-reported-for-kesimpta-treatment-of-individuals-with-early-non-highly-active-ms/2474006/Six-year open-label extension (OLE) results from the ALITHIOS clinical trial (NCT03650114) demonstrated that treatment with Kesimpta (ofatumumab; Novartis, East Hanover, NJ) was safe and effective for individuals with early multiple sclerosis (MS) and non-highly active disease taking continuous t
- Once Daily Dosing with Radicava ORS Was Not Superior to On/Off Dosing for the Treatment of People with ALShttps://practicalneurology.com/news/once-daily-dosing-with-radicava-ors-was-not-superior-to-onoff-dosing-for-the-treatment-of-people-with-als/2470615/Results of a phase 3b extension study presented at the 2024 meeting of the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium demonstrated the non-superiority of daily dosing of oral Radicava ORS (edaravone; Mitsubishi Tanabe Pharma America, Jersey City, NJ) compared with the current Food
- 2-Year Data Demonstrated Achievement of Key Motor Milestones in Children with SMA Treated with Evrysdihttps://practicalneurology.com/news/2-year-findings-show-evrysdi-treatment-linked-to-achievement-of-key-motor-milestones-in-children-with-sma/2470611/Two-year data from the ongoing phase 2 RAINBOWFISH clinical trial (NCT03779334) showed that the majority of children with spinal muscular atrophy (SMA) treated with Evrysdi (risdiplam; Genentech, South San Francisco, CA) presymptomatically as infants achieved key motor milestones. According to th
- 5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMShttps://practicalneurology.com/news/5-year-data-reveal-zeposia-treatment-was-associated-with-reduced-brain-volume-loss-in-patients-with-rms/2470586/Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple scleros
- Leqembi Treatment Associated with Sustained Reduction in Cognitive Decline According to 3-Year OLE Resultshttps://practicalneurology.com/news/leqembi-treatment-associated-with-sustained-reduction-in-cognitive-decline-according-to-3-year-ole-results/2470545/New 3-year open-label extension (OLE) results from the Clarity AD clinical trial (NCT03887455) presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) showed sustained reductions in cognitive decline in participants with early Alzheimer disease (AD) trea
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr